Recent clinical research on glucocorticoids and intravenous immunoglobulin therapy with myocarditis in children
10.3760/cma.j.issn.1673-4912.2013.05.004
- VernacularTitle:糖皮质激素和静脉丙种球蛋白在重症心肌炎救治中的应用进展
- Author:
Qingyou ZHANG
;
Junbao DU
- Publication Type:Journal Article
- Keywords:
Myocardiatis;
Treatment;
Children
- From:
Chinese Pediatric Emergency Medicine
2013;20(5):459-463
- CountryChina
- Language:Chinese
-
Abstract:
Myocarditis is one of the most common acquired heart diseases in children,and one of the most common causes of a pediatric dilated cardiomyopathy phenotype.The myocarditis is a difficult issue in the diagnosis and the optimal means of therapy.A recent Pediatric Cardiomyopathy Registry (PCMR) analysis in the largest group of pediatric myocarditis patients ever studied confirmed that the most common outcome in pediatric myocarditis was cardiac recovery,but approximately 30％ of pediatric myocarditis patients would die or undergo heart transplantation.Animal studies and adult experience suggested that autoimmunity might contribute to cardiac dysfunction in myocarditis.Immunosuppressive and immunomodulating therapy for pediatric myocarditis remains controversial.Small case series have shown benefit of these therapies in pediatric myocarditis.A limited number of biomarkers associated both good (recovery) and poor (death or transplantation) outcomes could be identified.We should do our best to find these biomarkers in the future.
